Intensive Lifestyle Intervention Reduces HFpEF Risk in High-Risk Diabetes: The Prescriptive Power of NT-proBNP
Posted inCardiology Diabetes & Endocrinology news

Intensive Lifestyle Intervention Reduces HFpEF Risk in High-Risk Diabetes: The Prescriptive Power of NT-proBNP

A post-hoc analysis of the Look AHEAD trial demonstrates that NT-proBNP levels can identify patients with type 2 diabetes who benefit most from intensive lifestyle interventions. ILI significantly reduced HFpEF risk in those with elevated or stable/decreasing NT-proBNP, supporting a biomarker-guided approach to prevention.
Elevated Cardiac Biomarkers Serve as Early Indicators of Structural Brain Damage and Cognitive Decline: Insights from the Hamburg City Health Study
Posted inCardiology Neurology news

Elevated Cardiac Biomarkers Serve as Early Indicators of Structural Brain Damage and Cognitive Decline: Insights from the Hamburg City Health Study

The Hamburg City Health Study reveals that elevated NT-proBNP and hs-cTnI are significantly linked to neurodegeneration and vascular brain injury. These cardiac biomarkers offer a non-invasive pathway for identifying patients at high risk for cognitive impairment and structural brain changes.
Impact of Structural Cardiac Abnormalities on the Efficacy and Safety of Sacubitril/Valsartan in Patients with Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure: Insights from the PARAGLIDE-HF Trial
Posted inCardiology Clinical Updates news Specialties

Impact of Structural Cardiac Abnormalities on the Efficacy and Safety of Sacubitril/Valsartan in Patients with Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure: Insights from the PARAGLIDE-HF Trial

The PARAGLIDE-HF trial demonstrates that sacubitril/valsartan significantly reduces NT-proBNP in patients with LVEF >40% and worsening heart failure, regardless of left ventricular hypertrophy or left atrial enlargement, but patients with both abnormalities face higher hyperkalemia risk.